Patients with type 2 diabetes mellitus (T2DM) and chronic kidney disease who received the SGLT2 inhibitor, canagliflozin, were less likely to have anemia than those on placebo, according to post-hoc analysis of a trial of the effectiveness of the antidiabetic for patients with nephropathy.
https://www.hcplive.com/view/canagliflozin-improves-anemia-diabetics-renal-impairment

